While Vanda Pharmaceuticals Inc has underperformed by -0.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VNDA rose by 4.18%, with highs and lows ranging from $6.36 to $3.81, whereas the simple moving average jumped by 7.82% in the last 200 days.
On October 31, 2024, H.C. Wainwright started tracking Vanda Pharmaceuticals Inc (NASDAQ: VNDA) recommending Buy. A report published by Cantor Fitzgerald on July 11, 2024, Initiated its previous ‘Overweight’ rating for VNDA. Jefferies also Downgraded VNDA shares as ‘Hold’, setting a target price of $12 on the company’s shares in a report dated February 25, 2022. BofA Securities Initiated an Buy rating on May 12, 2021, and assigned a price target of $22. Citigroup January 14, 2021d its ‘Buy’ rating to ‘Neutral’ for VNDA, as published in its report on January 14, 2021. Citigroup’s report from October 29, 2020 suggests a price prediction of $14 for VNDA shares, giving the stock a ‘Buy’ rating. Citigroup also rated the stock as ‘Neutral’.
Analysis of Vanda Pharmaceuticals Inc (VNDA)
Further, the quarter-over-quarter increase in sales is 5.43%, showing a positive trend in the upcoming months.
One of the most important indicators of Vanda Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -8.38% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.91, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and VNDA is recording 468.23K average volume. On a monthly basis, the volatility of the stock is set at 3.41%, whereas on a weekly basis, it is put at 3.61%, with a gain of 2.04% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.67, showing growth from the present price of $4.99, which can serve as yet another indication of whether VNDA is worth investing in or should be passed over.
How Do You Analyze Vanda Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 6.87%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 77.37% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VNDA shares are owned by institutional investors to the tune of 77.37% at present.
